Pell Bio-Med Technology Co., Ltd. (TPE:6949)

Market Cap	38.74B +731.6%
Revenue (ttm)	29.99M +62.9%
Net Income	-373.72M
EPS	-6.39
Shares Out	64.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	329,553
Average Volume	343,646
Open	588.00
Previous Close	600.00
Day's Range	585.00 - 620.00
52-Week Range	78.50 - 610.00
Beta	n/a
RSI	87.30
Earnings Date	Mar 13, 2026

About Pell Bio-Med Technology

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen receptor T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is also involved in the phase 1/2 multicenter study to evaluate the safety and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6949

Financial Performance

In 2024, Pell Bio-Med Technology's revenue was 19.63 million, an increase of 8.86% compared to the previous year's 18.03 million. Losses were -389.42 million, -2.34% less than in 2023.